Surrogate markers of response to cancer immunotherapy
- 1 March 2001
- journal article
- Published by Informa UK Limited in Expert Opinion on Biological Therapy
- Vol. 1 (2), 153-158
- https://doi.org/10.1517/14712598.1.2.153
Abstract
Clinically effective cancer immunotherapy has been sought for more than 100 years and has been recently applied most successfully in strategies that passively deliver immune effectors such as monoclonal antibodies (anti-CD20 for lymphoma and anti-HER2/neu for breast cancer), donor lymphocyte infusions in chronic myelongenous leukemia and non-myeloablative allogeneic peripheral blood progenitor transplants for renal cell carcinoma. There is mounting enthusiasm for strategies employing active stimulation of antitumour immune responses. These include vaccines based on tumour antigen proteins and peptides, autologous, allogeneic or gene-modified tumour cells, dendritic cells and antigen-encoding viral vector constructs. Indeed, randomised Phase III clinical trials of autologous tumour cell vaccines for colorectal cancer demonstrated an improvement in disease free survival and a trend toward improved overall survival [1]. Despite these preliminary successes, it is clear that the many strategies under development cannot all be evaluated for survival benefit in large clinical trials that require many years, patients and resources to complete. This highlights the need to develop intermediate markers to help prioritise which agents to test in prospective randomised Phase III trials.Keywords
This publication has 32 references indexed in Scilit:
- Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cellsJCI Insight, 1999
- Immunotherapy of Metastatic Malignant Melanoma by a Vaccine Consisting of Autologous Interleukin 2-Transfected Cancer Cells: Outcome of a Phase I StudyHuman Gene Therapy, 1999
- Evaluation of Immunological Responses in Patients with Ovarian Cancer Treated with the Anti-idiotype Vaccine ACA125 by Determination of Intracellular Cytokines—A Preliminary ReportHybridoma, 1999
- Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I studyGene Therapy, 1998
- Evaluation of the interferon-γ ELISPOT-assay for quantification of peptide specific T lymphocytes from peripheral bloodJournal of Immunological Methods, 1997
- Phenotypic Analysis of Antigen-Specific T LymphocytesScience, 1996
- Real time quantitative PCR.Genome Research, 1996
- Quantification of antigen specific CD8+ T cells using an ELISPOT assayJournal of Immunological Methods, 1995
- Longitudinal analysis of T cell receptor (TCR) gene usage by human immunodeficiency virus 1 envelope-specific cytotoxic T lymphocyte clones reveals a limited TCR repertoire.The Journal of Experimental Medicine, 1994
- T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.The Journal of Experimental Medicine, 1993